
NAPOLI 3, POUT, & Ivosidenib - Azole DDIs
OncoPharm
00:00
POUT overall survival and implications
John discusses the 5‑year overall survival (66% vs 57%), hazard ratio, p‑value, and adoption of adjuvant chemo as standard.
Play episode from 10:43
Transcript


